CLDX Celldex Therapeutics, Inc.
$29.50▲ +0.85%
Healthcare
Other
Volume 593.4K
Avg Volume (10D) 1.14M
Key Metrics & Fundamentals
Market Cap
$2.32B
P/E Ratio
–
Div Yield
0.00%
52W Range
22.10 - 45.14
% vs 50 MA
-15.63%
% vs 200 MA
-9.44%
RSI-14
41.6
MACD Histogram
+0.3200
Beta (1Y vs SPY)
1.22
Free Cash Flow
-$60.59M
Gross Rev
$22,000
Gross Profit
$22,000
EBITDA
-$86.84M
COGS
–
Operating Exp
$80.65M
Operating Income
-$80.62M
EBIT
-$80.62M
Pretax Income
-$73.50M
Net Income
-$73.50M
EPS (Diluted)
-0.94
Price & Volume History
Loading chart…
Recent News
Celldex Therapeutics (CLDX) Stock Looks Rich After Shareholder Investigation
Simply Wall St. · Oct 16, 2026 8:15 PM ET
Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?
Insider Monkey · Sep 23, 2026 8:41 AM ET
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte
Zacks · Sep 23, 2026 8:37 AM ET
Top Midday Decliners
MT Newswires · Sep 22, 2026 2:49 PM ET
CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’
Stocktwits · Sep 22, 2026 1:10 PM ET
Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses
MarketBeat · Sep 22, 2026 12:02 PM ET
4 Biotech Stocks With Key Clinical Readouts Expected This Fall
Zacks · Sep 22, 2026 10:51 AM ET
Celldex Shares Rise 8% as Barzolvolimab Meets Primary Endpoints in Two Phase 3 Trials
InvestorsHub · Sep 22, 2026 9:40 AM ET
Celldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria Trials
MT Newswires · Sep 22, 2026 7:31 AM ET
Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
GlobeNewswire · Sep 22, 2026 6:58 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See CLDX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.